All In Biotech

Drug Trial Radar · NCT05291091

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 244 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

244

Actual

Start

Nov 10, 2022

Primary completion

Sep 7, 2026

Study completion Sep 7, 2026

Sponsor

Lead sponsor
Edgewise Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Medpace, Inc.; ImagingNMD; SYSNAV
First posted
Mar 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 175 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker.

Conditions

  • Becker Muscular Dystrophy

Interventions

  • Sevasemten 10 mgDrug

    Sevasemten is administered orally once per day

  • Sevasemten 5 mgDrug

    Sevasemten is administered orally once per day

  • Sevasemten 12.5 mgDrug

    Sevasemten is administered orally once per day

  • PlaceboDrug

    Placebo is administered orally once per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of treatment emergent adverse events in those treated with sevasemten or placeboTime frame: 12 months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
  2. Severity of treatment emergent adverse events in those treated with sevasemten or placeboTime frame: 12 months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
  3. Change from Baseline in serum Creatine KinaseTime frame: Averaged across Months 6, 9, 12 Months (CANYON Cohorts 1, 2)
  4. Change from Baseline in total North Star Ambulatory Assessment scoreTime frame: 18 months (GRAND CANYON Cohort 6)

Locations

51 sites in 12 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • UC San Diego

    La Jolla, California

  • UCLA Medical Center

    Los Angeles, California

  • UC Irvine Medical Center

    Orange, California

  • Stanford Neuroscience Health Center

    Palo Alto, California

  • UC Davis Medical Center

    Sacramento, California

  • UC Denver

    Aurora, Colorado

  • University of Florida

    Gainesville, Florida

  • Rare Disease Research

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Kennedy Krieger Institute

    Baltimore, Maryland

  • University of Massachusetts Memorial Medical Center

    Worcester, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • University of Rochester Medical Center

    Rochester, New York

  • Rare Disease Research, LLC NC

    Hillsborough, North Carolina

  • University of Cincinnati Gardner Neuroscience Institute

    Cincinnati, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • National Neuromuscular Research Institute

    Austin, Texas

  • Neurology Rare Disease Center

    Denton, Texas

  • Virginia Commonwealth University Health

    Richmond, Virginia

  • St Vincent's Hospital Melbourne

    Fitzroy, Australia

  • Universitaire Ziekenhuizen Leuven

    Leuven, Belgium

  • Centre Hospitalier Régional de la Citadelle

    Liège, Belgium

  • University Hospital Gent

    Ghent, Belgium, Belgium

  • Rigshospitalet

    Copenhagen, Denmark

  • Centre de Reference des Maladies Neuromusculaires et de la SLA - AP-HM Hopital de La Timone

    Marseille, France

  • CHU de Nantes

    Nantes, France

  • CHU de Nice - Hopital Pasteur 2 - Centre de reference des Maladies Neuromusculaires

    Nice, France

  • AP-HP Hopital Pitie-Salpetriere

    Paris, France

  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen

    Munich, Germany

  • Hadassah University Hospital

    Jerusalem, Israel

  • Schneider Children's Hospital of Israel

    Petah Tikva, Israel

  • Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano

    Milan, Italy

  • Azienda Ospedale - Università Padova

    Padova, Italy

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.